Eflapegrastim

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

LymphomaSolid TumorNeutropenia

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

1

Eflapegrastim

Spectrum Pharmaceuticals, Inc

Approved

32

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

43

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—4

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—5

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—6

PEG-Intron

Merck & Co.

Preclinical

17

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

38

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

29

JY231

SShenzhen Genocury Biotech Co., Ltd.

Preclinical

110

CAR-T Therapy

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

2Show 11 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Neutropenia2 trials

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Completed·Spectrum Pharmaceuticals, Inc·Phase 1·NCT04187898·59 enrolled

Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy

Unknown status·—·Phase 4·NCT05949333·100 enrolled

Solid Tumor1 trial

A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Recruiting·Spectrum Pharmaceuticals, Inc·Phase 2·NCT04570423·40 enrolled

Details

Drug Info

Related News